Cargando…
Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss‐of‐function variant
Vinpocetine is a synthetic derivative of the alkaloid vincamine and has been used as a dietary supplement for decades. Following a positive report of the use of vinpocetine in a patient with a loss‐of‐function GABRB3 variant, we here describe another patient with a loss‐of‐function GABRA1 variant (p...
Autores principales: | Gjerulfsen, Cathrine E., Mieszczanek, Tomasz S., Johannesen, Katrine M., Liao, Vivian W. Y., Chebib, Mary, Nørby, Helene A. J., Gardella, Elena, Rubboli, Guido, Ahring, Philip, Møller, Rikke S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424645/ https://www.ncbi.nlm.nih.gov/pubmed/37434477 http://dx.doi.org/10.1002/acn3.51838 |
Ejemplares similares
-
Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies
por: Absalom, Nathan L., et al.
Publicado: (2022) -
Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy
por: Bai, Yun-Fei, et al.
Publicado: (2019) -
Correction to: Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy
por: Bai, Yun-Fei, et al.
Publicado: (2020) -
A standardized polyherbal preparation POL-6 diminishes alcohol withdrawal anxiety by regulating Gabra1, Gabra2, Gabra3, Gabra4, Gabra5 gene expression of GABA(A) receptor signaling pathway in rats
por: Sharma, Lalit, et al.
Publicado: (2021) -
Editorial: SLC6A1: the past, present and future
por: Johannesen, Katrine M., et al.
Publicado: (2023)